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Plant-virus-based vaccines have emerged as a promising avenue in vaccine development. This report describes the engineering of an
innovative vaccine platform using the papaya mosaic virus (PapMV) capsid protein (CP) as a carrier protein and a C-terminal fused hepatitis C
virus (HCV) E2 epitope as the immunogenic target. Two antigen organizations of the PapMV-based vaccines were tested: a virus-like-particle
(VLP; PapMVCP-E2) and a monomeric form (PapMVCP27–215-E2). While the two forms of the vaccine were both shown to be actively
internalized in vitro in bone-marrow-derived antigen presenting cells (APCs), immunogenicity was demonstrated to be strongly dependent on
antigen organization. Indeed, C3H/HeJ mice injected twice with the multimeric VLP vaccine showed a long-lasting humoral response (more than
120 days) against both the CP and the fused HCV E2 epitope. The antibody profile (production of IgG1, IgG2a, IgG2b, IgG3) suggests a Th1/Th2
response. Immunogenicity of the PapMV vaccine platform was not observed when the monomer PapMVCP-E2 was injected. These results
demonstrate for the first time the potential of the PapMV vaccine platform and the critical function of multimerization in its immunogenicity.
© 2007 Elsevier Inc. All rights reserved.Keywords: Vaccination; Virus-like particles (VLPs); Chimeric plant virus; Epitope carrierIntroduction
In general, vaccines against viral diseases are based on
attenuated or chemically inactivated live viruses (Ada, 2001). In
the case of vaccine development against new emerging
infectious diseases such as human immunodeficiency virus⁎ Corresponding author.
E-mail address: denis.leclerc@crchul.ulaval.ca (D. Leclerc).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.01.011(HIV), the application of this traditional approach raises
obvious safety issues due to possible reversion, recombination
or mutation. Therefore, the development of novel vaccine
platforms is urgently needed and is considered a priority for
global health improvement over the next 5–10 years, most
notably in developing countries (Daar et al., 2002).
Among the numerous new approaches to vaccine develop-
ment, virus-like particles (VLPs), made of viral nucleocapsids,
have emerged as a promising strategy. VLPs are composed of
viral structural proteins that retain the ability to self-assemble
60 J. Denis et al. / Virology 363 (2007) 59–68without requiring the presence of the viral genome: they have
been shown to be highly immunogenic and avoid the above-
mentioned safety issues (Noad and Roy, 2003). The ability of
VLPs to stimulate an adaptative immune response relies on
several properties: the average diameter of VLPs (<0.05 μm),
which is optimal for uptake of the VLPs by dendritic cells (Fifis
et al., 2004); efficient activation of the antigen presenting cells
(APCs) (Lenz et al., 2003); induction of CD8+ activation by a
cross-priming mechanism (Ruedl et al., 2002); potent stimula-
tion of a B-cell mediated response by direct cross-linking of the
BCR on B cells. This latter property was first demonstrated in
studies using organic polymers decorated with haptens, which
proved that 20–25 haptens spaced by 5–10 nm were enough for
T-cell-independent B-cell activation (Dintzis et al., 1976),
(Mond et al., 1995). These results were subsequently illustrated
using various viral models, for example by comparing the
immunogenicity of a multimeric antigen versus the immuno-Fig. 1. Purification and characterization of recombinant proteins. (A) PapMVCP, the
fused to a 6xHis tag (6H) located at the C-terminus of the protein. The hepatitis C viru
the PapMVCP and the 6H tag in PapMVCP-E2 and PapMVCP27–215-E2. (B) Purific
nickel column. The purity of the recombinant proteins was confirmed by SDS–PAGE
anti-PIII-E2 antibody (right). (C) Electron microscopy of PapMVCP virus-like part
200 nm.genicity of its less organized or soluble counterparts (Bachmann
et al., 1995; Baschong et al., 2003; Dintzis et al., 1976;
Justewicz et al., 1995; Loor, 1967; Milich and McLachlan,
1986) or by showing the ability of VLPs exhibiting a self-
epitope to break tolerance (Bachmann et al., 1993; Chackerian
et al., 2001; Jegerlehner et al., 2002). Thus, the displayed array
of antigens in a repetitive structure on viral, or VLP, surfaces
was proposed to be important for the B-cell mediated response.
It was suggested that the high immunogenicity of hepatitis B
virus (HBV) VLPs comes from its ability to synergize both T-
cell-independent activation of B cells by direct cross-linking of
BCR and T-cell-dependent activation of B cells (Milich and
McLachlan, 1986).
To date, two VLP vaccines, HBVand human papillomavirus
(HPV), have been shown to function efficiently in humans
(Fagan et al., 1987; Harper et al., 2004). VLPs derived from
other viral pathogens, such as HIV-1 and hepatitis C virusmultimeric PapMVCP-E2 and the monomeric PapMVCP27–215-E2 forms were
s (HCV) peptide (E2511–530) derived from envelope protein E2 is fused between
ation of recombinant proteins by affinity chromatography using the 6H tag and a
(left), and the presence of the E2 epitope was confirmed by western blot using an
icles (VLPs), (D) PapMVCP-E2 VLPs and (E) PapMVCP27–215-E2. Scale bars
Fig. 2. Comparison of the pro-inflammatory response of PapMVCP and
lipopolysaccharides (LPS). Dorsal air pouches were raised in 10- to 12-week-old
CD1 mice. One milliliter of endotoxin-free PBS alone; PBS containing 0.05, 1
or 1000 EU/ml LPS; or recombinant PapMVCP (10 μg/ml) were injected into
the air pouches. Migrating leukocytes in pouch exudates were harvested and
counted 6 h after treatment. Data represent the mean±SEM of 5 mice in each
case. These results are representative of two identical and independent
experiments. *Significant (P<0.05) differences between cell recruitment levels
as determined by Dunn's multiple comparison test.
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be proven in humans (Noad and Roy, 2003). Alternatively, the
use of VLPs from plant viruses as epitope presentation
systems has triggered much interest. Indeed, plant viruses
combine three characteristics essential to triggering a humoral
response and memory: (1) they are comprised mainly of
proteins that are highly immunogenic, (2) they are phylogen-
etically distant from the mammalian immune system, and (3)
they possess a complex and repetitive organization. Cowpea
mosaic virus (CPMV), tobacco mosaic virus (TMV), alfalfa
mosaic virus (AlMV) and potato virus X (PVX) have been
successfully produced in plants as vaccine platforms present-
ing peptides of interest (Canizares et al., 2005), and some
vaccines have been proven to be protective in various diseases
models (reviewed in Streatfield and Howard, 2003). Further-
more, the expression of Johnson grass mosaic virus coat
protein (CP) in E. coli (Saini and Vrati, 2003) led to the
formation of VLPs that were used as a recombinant
vaccination platform conferring protection after challenge
against Japanese encephalitis virus. Following the observation
that expression of the papaya mosaic virus (PapMV) CP in
E. coli also led to the self-assembly of VLPs composed of
several hundred CP subunits organized in a repetitive manner
(Tremblay et al., 2006), the potential of PapMV as a
recombinant peptidic vaccine platform was tested. An epitope
from the HCV E2 glycoprotein was fused to the PapMV CP,
resulting in the production of a new recombinant VLP
platform (PapMVCP-E2). The fused HCV peptide (511–
530) belongs to a larger region (411–613) of the E2
glycoprotein containing three main antibody (Ab) determi-
nants that can prevent the binding of HCV to its CD81
receptor on human cells (Lechner et al., 1998). Furthermore,
the critical function of multimerization in triggering a humoral
response, already demonstrated in mammalian virus models,
was evaluated for the first time using a plant virus model, by
comparing the immunogenicity of a recombinant plant VLP
and its monomeric counterpart. A monomeric mutant was
generated by deletion of the 26 first amino acids of the CP
(PapMVCP27–215); this protein (referred to as PapMVCP27–215-
E2 in this report) was used to express the same epitope as the
multimeric protein and its performance as a vaccine platform
was compared in vivo with the PapMV VLP-based vaccine
platform. Importantly, this monomeric form of PapMV CP,
which is unable to self-assemble in E. coli, has previously been
reported as having the same secondary structure as native CP
(Lecours et al., 2005).
In this report, we show that the recombinant multimeric
PapMV vaccine platform is able to trigger a strong and long-
lasting immune response against a C-terminal fused epitope.
The antibody response profile directed against the epitope
suggests a balanced Th1/Th2 response. Notably, the same
platform lost its immunogenic properties when injected as a
monomeric protein, validating the finding that a repetitive
organization is one of the key properties of molecules triggering
an immune response in the mammalian immune system. This is
the first demonstration of the critical function of a multimeric
structure for a plant-virus-based platform.Results
Production of recombinant multimeric and monomeric forms of
PapMV CP
Expression of PapMVCP in E. coli generates VLPs that are
similar in appearance to the wild-type virus purified from the
leaves of infected papaya plants (Tremblay et al., 2006). To
examine the ability of PapMVCP fused to an epitope from the
HCV E2 glycoprotein to assemble into VLPs, recombinant
PapMVCP, PapMVCP-E2 and the monomeric form
PapMVCP27–215-E2 (Fig. 1A) were expressed in E. coli and
purified using an easy procedure (see Materials and methods).
SDS–PAGE analysis revealed that there were no significant
differences in the yield of the various recombinant proteins (Fig.
1B, left panel), and immunoblotting directed against the E2
epitope indicated that no trimming of the peptide had occurred
(Fig 1B, right panel). Note that the apparent molecular weights
of PapMVCP-derived proteins on SDS–PAGE are slightly
higher than expected (Fig. 1B, left panel; observed 30–33 kDa
vs predicted 23–26 kDa), as previously noted (Lecours et al.,
2005; Tremblay et al., 2006). As expected, an immunoblot
using antibody directed to the E2 peptide confirmed that both
the monomeric (PapMVCP27–215-E2) and the multimeric form
(PapMVCP-E2) harbor the E2 fusion (Fig. 1B, right panel).
Endotoxin levels were always below 0.005 EU/μg of protein.
Electron microscopy (EM) confirmed that addition of the E2
peptide at the C-terminus of PapMVCP did not affect the ability
of the protein to self-assemble into VLPs (Fig. 1D), although the
particles were notably shorter than VLPs formed by recombinant
PapMVCP (Fig. 1C). Confirming previous results (Lecours
et al., 2005), the monomeric form PapMVCP27–215-E2 was
unable to form VLPs (Fig. 1E). PapMVCP-E2 VLPs were
variable in length, with a size range of 201±80 nm. A length
of 201 nm would represent 560 copies of the CP presenting
the E2 peptide in a repetitive fashion. The secondary structures
of the purified proteins were determined using circular
dichroism spectrophotometry and were shown to be very
similar to those previously reported (data not shown) (Lecours
et al., 2005).
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Some commonly used adjuvants, such as alum, have been
described as mediating an inflammatory episode at the site of
injection (Brewer, 2006). This characteristic can be very useful
for the induction of a strong immune response. To test the pro-
inflammatory properties of PapMVCP VLPs, we used the
murine air pouch model. Injection of 10 μg of PapMVCP VLPs
failed to induce the recruitment of leukocytes into the pouch of
CD1 mice 6 h after treatment. In contrast, injection of
lipopolysaccharides (LPS) at doses of 1000 and 1 EU was
very effective in inducing the recruitment of leukocytes (Fig. 2).Fig. 3. Comparative internalization of PapMVCP-E2 and PapMVCP27–215-E2 in antig
incubated for 2 h at 37 °C with 25 μg of PapMVCP-E2 or PapMVCP27–215-E2. Cells
methods. The recombinant proteins were detected with a mouse anti-rabbit antibody
rabbit polyclonal antibodies. (A, B) Internalization of PapMVCP-E2 VLPs (A)
Internalization of the monomeric (PapMVCP27–215-E2) or multimeric (PapMVCP
microscopy. Two representative images of each treatment are shown. Slides were sca
scanned cells are shown. An overlay of the phase contrast and the green channel
experiments. The control (Untreated) is unstimulated cells labeled with PapMVCP rThis result suggests that PapMVCP VLPs are not pro-
inflammatory after 6 h and that the very low level of LPS in
our proteins samples (<0.005 EU/μg) would not exert any
notable immunogenic effects in subsequent experiments.
Comparative internalization of PapMVCP-E2 and
PapMVCP27–215-E2 in bone-marrow-derived dendritic cells
The uptake of VLPs by APCs was previously shown to be
important for the induction of the immune response (Lenz et al.,
2003; Gamvrellis et al., 2004). Therefore, we tested the capacity
of the monomeric (PapMVCP27–215-E2) and the multimericen presentation cells (APCs) derived from bone marrow cells. 1×106 APCs were
were fixed and processed for immunofluorescence as described in Materials and
conjugated to alexa 488 (green), which in turn detected the primary PapMVCP
and PapMVCP27–215-E2 (B) in APCs as measured by flow cytometry. (C)
-E2) PapMV vaccine platform in APCs analyzed by laser scanning confocal
nned sequentially with a 488-nm laser line. Optical slices from the middle of the
is presented. The images are representative of two identical and independent
abbit polyclonal antibodies and the secondary alexa 488 anti-rabbit antibody.
Fig. 4. Kinetics of the antibody response in C3H/HeJ mice injected
subcutaneously twice (day 0 and day 15) with 25 μg of the multimeric
PapMV vaccine platform (PapMVCP-E2), its monomeric counterpart
(PapMVCP27–215-E2), HCV E2 peptide (2 μg) alone or PBS. (A) IgG antibody
response specific for the PapMV capsid protein. ELISA plates were coated with
PapMVCP or PapMVCP27–215. (B) IgG antibody response against the HCV E2
epitope. ELISA plates were coated with the HCV E2 peptide fused to the CaMV
pIII carrier protein (see Materials and methods). (C) IgG antibody response to
the CaMV pIII carrier protein alone. (D) IgG isotyping of the HCV E2 epitope
antibody response, showing a balanced Th1/Th2 antibody isotyping profile.
Only isotyping profiles of sera from mice injected with PapMVCP-E2 or PBS
are presented in this figure. The results are expressed as antibody endpoint titer,
defined as when the OD value is 3-fold higher than the background value
obtained with a 1:50 dilution of serum from PBS-injected mice. Data represent
the average of antibody titers from 4 (A) or 5 (B–D) mice. These results are
representative of two identical and independent experiments. Black arrows on
the graphs indicate the booster injections on day 15.
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derived APCs enriched in bone-marrow-derived dendritic cells
(BMDDC). Equivalent amounts (25 μg) of PapMVCP-E2 and
PapMVCP27–215-E2 were incubated with 1×10
6 cells for 2 h at
37 °C. Flow cytometry analysis showed that APCs become
efficiently immunolabeled (>90%) by both the multimeric (Fig.
3A) and the monomeric forms (Fig. 3B). To visualize the
interaction between the recombinant proteins and the APCs,
treated cells were observed by confocal microscopy. For both
proteins, the immunolabeled PapMVCP signal was clearly
vesicular, intracytoplasmic and perinuclear (Fig. 3B). Both
recombinant proteins were efficiently internalized in APCs.
The humoral response depends on multimerization of the
plant-virus-based vaccine platform
To examine the capacity of PapMVCP VLPs to induce an
immune response, C3H/HeJ mice were injected subcuta-
neously with 25 μg of the recombinant VLPs (PapMVCP-E2)
or 25 μg of the monomeric form (PapMVCP27–215-E2). The
amount of E2 peptide present in each dose is estimated at
2 μg. A booster dose was given on day 15 after primary
immunization. Mice sera were assayed for anti-PapMVCP,
PapMVCP27–215 and anti-E2 peptide antibodies. Anti-CP IgG
was clearly detected in mice immunized with PapMVCP-E2
on day 12, while only a low level of anti-CP was detected in
the sera of mice vaccinated with PapMVCP27–215-E2, even
after the booster on day 15 (Fig. 4A). To detect anti-peptide
antibodies, ELISA plates were coated with either the carrier
protein alone (pIII) or carrier protein fused to the HCV E2
epitope (PIII-E2). The carrier protein fusion was used to
detect anti-peptide IgG. The PIII carrier stabilizes the peptide
and eases the purification because of its thermostability
(Leclerc et al., 1998). Only sera of mice immunized with
PapMV-E2 showed IgG antibodies against the carrier protein
fused to the E2 peptide (PIII-E2), and the titer increased after
the booster on day 15 (Fig. 4B). No antibody response was
detectable against the carrier alone (PIII) for all sera (Fig.
4C). To examine the specificity of the antibody response
elicited by the VLPs, sera from mice immunized with VLPs
without the E2 peptide or with another peptide (derived from
HCV E1 glycoprotein) were tested against PIII and PIII-E2.
Antibodies to these latter proteins were not detected,
confirming the specificity of the E2 antibodies (data not
shown). The multimeric form was able to trigger a long-
lasting response against both the CP and the E2 epitopes.
Moreover, from day 23 to day 120, the antibody titer against
the capsid decreased only on a 1 log2 scale (Fig. 4A), while
the antibody titer against the peptide decreased on a 4 log2
scale (Fig. 4B). Isotyping of the anti-peptide antibodies
revealed a Th1/Th2 balanced profile, with a prevalence of
IgG1, IgG2a and IgG2b antibodies and a less pronounced
production of IgG3 (Fig. 4D). A similar immunization
protocol was performed in Balb/c mice with identical results:
the same Th1/Th2 profile was observed with a similar IgG
isotyping profile directed against both the PapMVCP and the
E2 epitope (data not shown).Reactivity of human sera against the HCV E2 peptide
presented by the PapMV platform
An important issue in peptidic vaccination is good mimicry
of the fused epitope. Consequently, to check if the peptide
derived from the HCV surface glycoprotein E2 that is fused to
the C-terminal of the PapMV CP can be recognized by serum
from HCV-infected patients, sera from several healthy donors
Table 1
E2511–530-specific antibody titres found in HCV-infected patients
Patient No/genotype HD⁎ 1/1a 2/1a 3/1a 4/1a 5/1a 6/1a 7/1a 8/3
PapMVCP VLPs 0 0 0 0 0 0 0 0 0
PapMVCP-E2 VLPs 0 0 0 0 0 0 1/800 0 0
pIII 0 0 0 0 0 0 0 0 0
pIII-E2 0 0 0 0 0 1/25 1/200 0 0
⁎ HD: healthy donors, the sera of 15 healthy donors were mixed in equal
proportion.
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PapMVCP-E2 VLPs (Table 1). Of the eight sera from HCV
patients tested, one (patient no. 6) reacted with E2 peptide at the
surface of PapMVCP-E2 VLPs, while the same serum did not
react against PapMVCP VLPs (Table 1). When the E2 peptide
was fused in the context of the carrier protein PIII, the same
serum was reactive to the peptide. A second serum (patient no.
5) also reacted very weakly, close to the background level, to the
E2 peptide. Although the same sera (patient no. 6) were clearly
reactive with two anti-E2 detection systems (PIII/PIII-E2 and
PapMVCP27–215/PapMVCP27–215-E2), the differences between
the antibody titers could not be satisfactorily explained.
Discussion
This is the first report to compare the immunogenicity of
multimeric and monomeric forms of a plant virus vaccine
platform expressing the same B-cell epitope. Clearly, PapMV
VLPs are immunogenic in mice whereas the monomeric
forms are not. The VLP differs from the monomeric form in
only two features: the multimerization of the subunit into a
repetitive structure, and the RNA from E. coli located inside
the VLPs. Both of these features were previously shown to
play a role in the activation of the immune response; their
combination in VLPs is likely to play an important role in
their immunogenicity.
The central function of multimerization in triggering a
humoral response in the PapMV vaccine platform model is
consistent with previous studies in this area. Multimerization has
been proven to be important in the immunogenicity of human
viral vaccine platforms (Milich and McLachlan, 1986) or murine
viruses (Bachmann et al., 1995), (Bachmann et al., 1993).
Efficient direct cross-linking of BCR (Bachmann et al., 1995),
(Zinkernagel, 2003) and facilitation of antigen internalization in
APCs such as dendritic cells have been proposed as largely
explaining the ability of VLPs to trigger an efficient antibody
response and class-switching via cooperation of CD4+ activated
lymphocytes (Gamvrellis et al., 2004). Any model designed to
test the influence of antigen organization on humoral response
has to address the two main phenomena influencing the level of
activation of naive B cells, i.e., antigen binding to BCR and
cross-linking of BCRs (Brunswick et al., 1988), separately. In
other words, it is necessary to ensure that the lack of
immunogenicity of a monomeric antigen compared to a multi-
meric antigen is not due to alteration of its binding capacity to
specific BCRs rather than a reduced BCR cross-linking ability.
Consequently, the tertiary structure required for BCR recognitionmust be similar for both the multimeric and monomeric forms of
the antigen tested. As the monomeric form of PapMV CP was
previously shown to have the same secondary structure as the
multimeric CP, and was amenable to an extensive 3D NMR
study (Lecours et al., 2005), our model allowed us to properly
address the differential ability of the multimer and monomer to
cross-link BCRs. This important structural control was not
included in previous studies that generated monomeric antigen
by denaturing VLPs by treating with SDS and 2-mercaptoethanol
(Milich and McLachlan, 1986), treating flagellin with acid
treatment (Feldmann and Easten, 1971) or by producing
monomers in E. coli (Jegerlehner et al., 2002). None of these
latter studies presented any evidence of secondary and tertiary
structural conservation between the multimeric and monomeric
forms. In our case, the monomeric form was unable to trigger a
humoral response against the C-terminal presented peptide,
while the multimeric form was able to induce a long-lasting
response (120 days) against both the PapMVCP and the exposed
epitope after two injections. This dramatic difference is unlikely
to be due to degradation of the monomeric vaccine or trimming
of the E2 fused peptide as our SDS–PAGE and immunoblotting
analyses confirmed the integrity of the 2 vaccine forms and the
uniform concentration of E2 peptides (Fig. 1). It is likely that the
monomeric protein is unable to generate efficient activation of B
cells, which could reasonably be attributed to a weak BCR cross-
linking capacity. In contrast, injection of the multimer resulted in
the creation of a pool of antibody-producing cells and memory B
cells.
Since the class-switching (production of IgG1, IgG2a,
IgG2b, IgG3) observed after injection of PapMVCP-E2 is a
process that requires the contribution of CD4+ lymphocytes
activated by APCs (Zinkernagel, 2003), internalization by
bone-marrow-derived APCs was evaluated. As expected, the
multimer was actively internalized by APCs. Interestingly, no
difference in the magnitude of internalization into APCs was
seen between the monomeric and the multimeric vaccine
platform. In addition, differences between the monomeric and
the multimeric vaccines in the in vivo capacity to activate DCs
could not be demonstrated 6 h post-injection (data not shown).
Therefore, the difference in immunogenicity could depend on
the MHC class II processing of the antigen and subsequent
activation of specific T cells, which, as previously demonstrated
(Milich et al., 1997), may be more efficient with VLPs than with
the monomeric form. The function of B cells as APCs could
also be a key element; the same author also demonstrated that B
cells could process HBV VLPs and activate a T-cell response
105 times more efficiently than DCs and MOs.
PapMVCP VLPs also contain an RNA of bacterial origin
that was used as a scaffold for PapMV CP self-assembly in the
bacteria (Tremblay et al., 2006). As in the purified plant virus,
the RNA represents 5% (w/w) of the mass of the VLP (Erickson
et al., 1976). In contrast, the monomeric form of the CP is not
associated with RNA because its RNA binding activity is
lacking (Lecours et al., 2005). Although the bacterial RNA is
only a minor component of the VLP, we cannot exclude that it
contributes to adjuvanticity by, for example, activating APCs as
established previously (Kariko et al., 2005; Sugiyama et al.,
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PapMV VLPs of other bacterial components with strong
adjuvanticity, such as LPS, was shown to be negligible in two
different ways. Firstly, immunization with PapMV VLPs in
LPS-sensitive mice (Balb/c, data not shown) and LPS hypo-
responsive mice C3H/HeJ (Fig. 4) led to the same humoral
immune response against both the platform and the C-fused
epitope. Secondly, PapMV VLPs with very low LPS content
(<0.005 EU/μg) were unable to trigger the recruitment of innate
immune cells in the air pouch model after 6 h, contrasting with
the high recruitment capacity of LPS (Fig. 2). Taken together,
our results confirm the conclusion that the immunogenic effect
of recombinant PapMVCP VLPs does not derive from LPS-like
pro-inflammatory properties. The only other reported case of
use of VLPs from a plant virus produced in E. coli made no
mention of determination of the LPS content of the proteins
injected or the influence of LPS content on the observed results
(Saini and Vrati, 2003).
The Th1/Th2 profile of antibodies triggered by the PapMV
recombinant protein without the use of any adjuvants suggests
that this newly described vaccine platform potentially triggers
a broader immune response than other plant-virus-based
platforms. Indeed, antibody isotyping has previously suggested
plant virus vaccine platforms to be biased toward a Th1
response (Marusic et al., 2001; McInerney et al., 1999) and
cytokine secretion (Piazzolla et al., 2005). Even the presence of
a commercial adjuvant with VLPs did not modify the Th1 bias
(Marusic et al., 2001). A balanced Th1/Th2 antibody profile
could increase the immune effector mechanisms of the humoral
response such as neutralization or antibody-dependent cell-
mediated cytotoxicity (ADCC) additional experiments would
be necessary to investigate the potential of the PapMV
platform to trigger these mechanisms in the HCV model.
Moreover, the findings that the PapMV vaccine platform was
able to trigger a pool of all antibody isotypes against the HCV
E2 peptide and that serum from one HCV patient was clearly
able to recognize the E2 peptide fused to the PapMV platform
could indicate that this platform is suitable for triggering, for
example, ADCC directed against hepatocytes exhibiting E2
protein on their surface as described in a clinical report by
Nattermann et al. (2005), potentially helping to reduce the
severity of the disease. In addition, a recent report (Leclerc et
al., in press) demonstrated the capacity of the PapMV platform
to activate human specific CD8+ lymphocytes in vitro by cross-
priming. Taken together, these results suggest that the
development of a vaccination platform based on PapMV
VLPs against infectious diseases such as HCV, which requires
both a protective CD8+ and a humoral response (Houghton and
Abrignani, 2005), is a promising avenue of research.
Materials and methods
Cloning and engineering of the PapMV coat protein
The PapMV CP gene was amplified by RT/PCR from
isolated viral RNA using primers 5′-AGTCCCATGGCATC-
CACACCCAACATAGCCTTC-3′and 5′-GATCGGATCCT-TACTAATGGTGATGGTGATGGTGACGCGTGGTAC-
TAGTTTCGGGGGGTGGAAGGAATTGGATGGTTGG-3′
and cloned as an NcoI/BamHI fragment in pET 3D (New
England Biolabs). To generate the PapMVCP-E2 construct,
CCACCGATCGTAGCGGTGCGCCGACCTACAGCTGG-
GGTGCGAACGATACGCGTCATG-3′ and 5′-CATGACGC-
GTATCGTTCGCACCCCAGCTGTAGGTCGGCGCACCGC-
TACGATCGGTGGTACCCACCACCACACTAGTGATC-3′
were annealed together and digested with SpeI and MluI before
ligation into the SpeI/MluI-linearized PapMVCP clone. The
expression vector for PapMVCP27–215-E2 was constructed from
the PapMVCP-E2 plasmid as follows: two oligonucleotides
(including an NcoI restriction site) designed to delete the 26
first amino acids of the PapMV CP were used for PCR: forward
5′-AGTCCCATGGCCGATCCAACGTCCAATCTTCTG-3′
and reverse 5′-ACGTCCATGGTATATCTCCTTCTTAAAG-3′.
The PCR product was then self-ligated. The expression vector for
PapMVCP27–215 was derived from the PapMVCP plasmid fol-
lowing the same procedure as for the construction of the
PapMVCP27–215-E2 clone. The sequences of all PapMV clones
were confirmed by DNA sequencing.
Cloning and engineering of the carrier protein (PIII)
A plasmid designed to express the cauliflower mosaic virus
(CaMV) pIII protein in E. coli has been previously described
(Leclerc et al., 1998). A truncated version of CaMV pIII
comprising the 74 N-terminal amino acids was generated using
primers 5′-AAACCCGGGGAATTCACCATGGCTAA-
TCTTAATCAGATCCAAAAG 3′ and 5′-GATCGGATC-
CTAACGCGTGGTACTAGTAGGTTGGGTACCTA-
AGGCTTC-3′. This truncated version harbored unique SpeI
and MluI sites that are convenient for cloning a peptide in
fusion with pIII. To generate a PIII-E2 construct, the
oligonucleotides E2 5′-GATCACTAGTGTGGTGGTG-
GGTACCACCGATCGTAGCGGTGCGCCGACCTA-
CAGCTGGGGTGCGAACGATACGCGTCATG-3′ and
5′-CATGACGCGTATCGTTCGCACCCCAGCTGTAGG-
TCGGCGCACCGCTACGATCGGTGGTACCCACCACCA-
CACTAGTGATC-3′ were annealed together and digested with
SpeI andMluI before ligation into the PIII clone linearized with
SpeI andMluI. The sequences of PIII clones were confirmed by
DNA sequencing. The E. coli expression strain BL21(DE3)
RIL (Stratagene) was transformed with PIII constructs, and
protein expression was induced with 1 mM IPTG for 16 h at
25 °C. Cells were pelleted by centrifugation and resuspended in
Tris–HCl pH 7.0, 20 mM NaCl, 1 mM EDTA and 0.02 mM
PMSF before lysis by sonication. The protein extracts were then
heated at 65 °C for 15 min and centrifuged at 15,000×g for
20 min at 4 °C. Incubation at 65 °C was repeated a second time.
The samples were incubated at 80 °C for 15 min and
centrifuged again for 20 min at 15,000×g. The chimeric pIII
protein is resistant to heat and remains soluble in the
supernatant after this treatment. The NaCl concentration was
adjusted to 150 mM and protein extracts were separated on a
Sephadex G-50 column to achieve 95% purity. The PIII protein
is referred to as the carrier protein in the text.
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PapMVCP27–215 and PapMVCP27–215-E2
Expression and purification of PapMVCP constructs were
performed as previously described with minor modifications
(Tremblay et al., 2006). Briefly, the bacteria were lysed
through a French press and then loaded onto a Ni2+ column,
washed with 10 mM Tris–HCl/50 mM Imidazole/0.5% Triton
X100 (pH 8), then with 10 mM Tris–HCl/50 mM Imidazole/
1% Zwittergent (pH 8) to remove endotoxin contamination.
For the PapMVCP and PapMVCP-E2 proteins, the eluate was
subjected to high speed centrifugation (100,000×g) for
120 min in a Beckman 50.2 TI rotor. The VLP pellet was
resuspended in endotoxin-free PBS (Sigma). Following
elution of the PapMVCP27–215 and PapMVCP27–215-E2
proteins, the solutions were dialyzed against PBS using a
6–8 kDa molecular weight cut-off membrane (Spectra). The
E2 peptide was synthesized by GLBiochem (Shanghai) Ltd
and resuspended in endotoxin-free PBS (Sigma). Protein
solutions were filtered using 0.45 μM filters before use. The
purity of the proteins was determined by SDS–PAGE and
confirmed by western immunoblot analysis using mouse
polyclonal antibodies generated against PIII-E2. The amount
of protein was evaluated using a BCA protein kit (Pierce). The
level of LPS in the purified protein was evaluated with the
Limulus test according to the manufacturer's instructions
(Cambrex) and was below 0.005 endotoxin units (EU)/μg of
protein.
Electron microscopy
Proteins were diluted in PBS and were absorbed for 3 min on
carbon-coated formvar grids. The grids were washed twice with
deionized water and stained with 2% uranyl acetate for 10 min
at room temperature. The grids were then observed on a Jeol
JEM220FS transmission electron microscope. Average VLP
length was evaluated by measuring 100 VLPs using Adobe
Photoshop software.
Immunization
Five 4-to 8-week-old C3H/HeJ mice (Charles Rivers
Laboratories) were injected subcutaneously with 25 μg of
PapMVCP-E2, PapMVCP27–215-E2 or the equivalent amount
of the E2 peptide (2 μg) or endotoxin-free PBS (Sigma).
Primary immunization was followed by one booster dose given
2 weeks later. Blood samples were obtained at different time
points and stored at −20 °C until analysis. All the experimental
protocols were approved by the Laval University animal
protection committee.
ELISA quantification
Costar High Binding 96-well plates (Corning, NY, USA)
were coated overnight at 4 °C with 100 μl/well of P3, P3E2,
PapMVCP, PapMVCP27–215, or PapMVCP-E2 diluted to a
concentration of 1 μg/ml in 0.1 M NaHCO3 buffer pH 9.6. Theplates were blocked with PBS/0.1% Tween-20/2% BSA
(150 μl/well) for 1 h at 37 °C. After washing three times with
PBS/0.1% Tween-20, sera were added in 2-fold serial dilution
(beginning with 1:50) and incubated for 1 h at 37 °C. Following
incubation, the plates were washed three times and incubated
with 100 μl of peroxidase-conjugated goat anti-mouse IgG,
IgG1, IgG2a, IgG2b (all from Jackson Immunoresarch) or IgG3
(Rockland) at a dilution of 1:10,000 in PBS/0.1% Tween-20/2%
BSA for 1 h at 37 °C. After three washes, the presence of IgG
was detected with 100 μl of TMB-S according to the
manufacturer's instructions; the reaction was stopped by adding
100 μl of 0.18 mM H2SO4 and the OD was read at 450 nm. The
results are expressed as antibody endpoint titer, determined
when the OD value is 3-fold the background value obtained
with a 1:50 dilution of serum from PBS-injected mice. For the
determination of antibody levels in human sera, the same
conditions were applied, except that the peroxidase-conjugated
goat anti-human IgG as secondary antibodies were used at a
dilution of 1:80,000. Sera from infected HCV patients were
provided by B. Willems (Hopital Saint Luc, CHUM): the results
are expressed as antibody endpoint titer, defined as the point at
which the OD value is 3-fold the background value obtained
with a 1:25 dilution of serum from a pool of sera from 15 non-
infected patients.
Air pouches in mice
Air pouches were raised in 10- to 12-week-old CD1 mice
(Charles River Laboratories). Experimental protocols were
approved by the Laval University animal protection committee.
Air pouches were raised on the dorsum by subcutaneous
injection of 3 ml of sterile air on days 0 and 3. On day 7, 1 ml of
recombinant PapMVCP (1 to 10 μg/ml), LPS (10 μg/ml) or
PBS was injected into the air pouches. Six hours after treatment,
the mice were killed by asphyxiation using CO2. The air
pouches were washed once with 1 ml PBS–5 mM EDTA and
then twice with 2 ml of PBS–5 mM EDTA, and the exudates
were centrifuged at 500×g for 5 min at room temperature. Cells
were counted with a hematocytometer following acetic blue
staining.
Bone marrow cell extraction and differentiation of APCs
Bone marrow progenitors cells were obtained from the femurs
of Balb/c mice and cultured for 6 days in dendritic cells
differentiation bone marrow medium (95% RPMI with 1%
penicillin–streptomycin and supplemented with 5% X63-GM-
CSF supernatant media culture; the X63-GM-CSF cell line was
provided by B. Ludewig, Research Department, Cantonal
Hospital, St. Gallen, Switzerland). Mediumwas partially replaced
on days 2 and 4. On day 6, the medium was replaced by medium
without LX63-conditioned medium. On day 7, enrichment of
APCs was verified by flow cytometry using FITC anti-CD11c
and PE-Cy5.5 anti-CD11b surface markers (BD Biosciences).
The preparation contained 25% of CD11c+ Cd11b+ cells, and
more than 80% of CD11b+ cells. We refer to this preparation as
APCs.
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To evaluate internalization of the PapMVCP-E2 or
PapMVCP27–215-E2 in APCs, 1 million bone-marrow-derived
APCs were incubated for 2 h at 37 °C with either 25 μg of
PapMV-E2 or PapMVCP27–215-E2. Briefly, cells were blocked
with PBS containing 10% FBS and anti-CD16/CD32 (1 μg/1
million cells) for 15 min at 4 °C. After 2 washes with PBS, cells
were fixed with PBS/2% paraformaldehyde for 10 min at room
temperature. After 2 washes with permeabilization buffer (PBS
10%/FBS 0.2%/Triton X-100), cells were incubated for 45 min
at 4 °C with rabbit polyclonal antibodies diluted 1:200 in per-
meabilization buffer. After 2 washes with permeabilization
buffer, cells were incubated for 45 min at 4 °C with the secondary
antibodies (anti-rabbit IgG alexa 488; Molecular Probes) diluted
1:5000 in permeabilization buffer. After washing with PBS, cells
were immediately analyzed with an EPICS-XL cytofluorometer.
Data analysis was performed using WINMDI2.8. The rabbit
polyclonal Ab used for detection was produced in our own faci-
lities: rabbit preimmune serum was used as a negative control.
Confocal microscopy
APCs were grown (200,000 cells/well) in 12-well plates
(Corning, NY, USA) containing sterile slides in the bottom
following the differentiation protocol described above. For
antigen internalization studies, 5 μg of antigen/200,000 cells
was used. The fixation, permeabilization and primary and
secondary antibodies incubation steps were as described for
flow cytometry. Slides were analyzed immediately with a
Fluoview Fv300 confocal microscope fitted with a ×60 oil
immersion objective. Fluorescence images were acquired sequen-
tially to avoid non-specific channel interference and by x–z
sectioning. Pictures were then digitally processed with Image J
software. Optical slices from the middle of the scanned cells are
shown in the figures.
Statistical analysis
Nonparametric Kruskal–Wallis and Dunn's multiple com-
parison tests were used for statistical analysis. A value of
P<0.05 was considered statistically significant. Statistical
analyses were performed with the program PRISM 3.03.
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